Government to raise NovoSeven insurance price by 35% on average

Published: 2009-07-23 06:59:00

Updated: 2009-07-23 06:59:00

The government said on July 21 that the insurance price of Novo Nordisk’s NovoSeven will increase by 35% on average, as the health ministry and Novo Nordisk reached an agreement over the controversial price negotiation.

NovoSeven is recombinant human coagulation Factor VIIa (rFVIIa), intended ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK